Madrigal Pharmaceuticals, Inc. (MDGL) Stock Price & Analysis

Madrigal Pharmaceuticals, Inc. (MDGL) closed at USD 453.34 on Thursday, October 22, 2026, down 1.01% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 457.96; the Oct 22, 2026 session ranged USD 452.08–462.5 on volume of 212,687 shares. Market capitalization is $10.47B, with a 52-week range of USD 393.61–615 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:37 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MDGL.md

Key facts (MDGL)

• Last four reported quarters (through Jun 30, 2026): revenue $1.28B, net income -$325M (-25.3% margin), free cash flow -$206M (SEC filings).
• Insider open-market sales, last ~7 months: 6 Form 4 filings, $11.8M; 3 not under a Rule 10b5-1 plan ($2.1M); 1 by opportunistic insiders (0 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 1.89 on a 1–5 scale) (19 analysts), mean target USD 685.22 (range 533–962).
• Total return with dividends: 1Y +7.0% vs S&P 500 +14.9%; 5Y +478.9% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD -1.09, revenue estimate $405M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MDGL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (MDGL)

P/S 8.2x · EV/Sales 7.8x · P/B 20.0x · FCF yield -1.97% · Earnings yield -3.10% · Net cash $498M · EV $9.98B

Insider sales (SEC Form 4, open-market, last ~7 months) (MDGL)

3 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (MDGL)

Consensus Buy (mean 1.89 on a 1–5 scale), 19 analysts; mean target USD 685.22 (low 533, high 962).

Rating changes, last 120 days:

Total return (dividends reinvested) (MDGL)

MDGL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 19, 2026.

MDGL customer concentration

In the period ended Jun 30, 2026, 5 direct customers each accounted for at least 10% (28%, 20%, 16%, 14%, 12%) of revenue, per the company's 10-Q filed Jul 30, 2026. The company does not name them.

MDGL company outlook (results filed Jul 30, 2026)

• “This patent is expected to provide protection into 2045. ▪ U.S.”
• “This patent is expected to provide protection into 2042. ◦ F4c: The USPTO also issued a new patent, U.S.”

Quoted word-for-word from the SEC 8-K results press release.

MDGL analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 10:37 UTC)

Technical Analysis (MDGL)

Nexqual's technical model rates MDGL "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:37 UTC.

Analyst Ratings (MDGL)

Wall Street analysts rate MDGL "Buy" based on 19 analysts, with a mean price target of USD 685.22 (range USD 533–962), per Nexqual as of October 23, 2026 at 10:37 UTC.

Earnings (MDGL)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Financials & Fundamentals (MDGL)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Financial Health Score (MDGL)

Nexqual rates Madrigal Pharmaceuticals, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:37 UTC.

Ownership (MDGL)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

Leadership (MDGL)

Madrigal Pharmaceuticals, Inc. is led by William J. Sibold, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:37 UTC.

Major Backers & Investors (MDGL)

Notable institutional backers of Madrigal Pharmaceuticals, Inc. include Baker Bros. Advisors, LP, RTW Investments LP, Jupiter Topco LLC, according to Nexqual as of October 23, 2026 at 10:37 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:37 UTC.

From Madrigal Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• In January 2026, we entered into an amendment to the Roche Agreement to provide us the full and exclusive right and discretion to control all patent term adjustments and patent term extensions applicable to Rezdiffra, including patents owned by Roche and jointly owned between the parties.
• Our success will depend in part on our ability to obtain and maintain patent and other proprietary protection for Rezdiffra and any current or future product candidates, technology and know-how, our ability to freely operate without infringing on the proprietary rights of others and our ability to establish proprietary rights and prevent others from infringing our proprietary rights.
• We monitor for activities that may infringe our proprietary rights, as well as the progression of third-party patent applications that may have the potential to interfere with the development of our business.
• We seek to protect our proprietary processes, in part, by confidentiality agreements and invention assignment agreements with our personnel, including consultants and commercial partners.

Partnerships

• The U.S. patent provides protection to February 2045 and was listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, in August 2025. •In July 2025, we entered into a Financing Agreement (as amended, the "Financing Agreement") with certain funds managed by Blue Owl Capital Corporation as the lenders (the "Lenders") and LSI Financing LLC as the administrative agent for the Lenders (the "Administrative Agent").
• In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.

Legal & Regulatory Risks (Item 1A, quoted)

• We will be required to demonstrate through adequate and well-controlled clinical trials that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in our target indications before we can seek regulatory approvals for commercial sale.
• We cannot be certain that any of our ongoing or future clinical trials will be successful, and any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.
• We make assumptions, estimates, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data.
• The requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement for marketing products outside the United States vary greatly from country to country and may require additional testing.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:37 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt